Mutation-specific antibodies using BRAF V600E (clone VE1) and RAS Q61R (clone SP174) are suitable for identifying the most prevalent mutations in thyroid tumors, while pan-TRK (clone EPR 17341) and ALK (cloned 5A4 and D5F3) are used to detect the overexpression of chimeric protein products resulting from kinase gene fusions, present in a small but clinically relevant subset of thyroid carcinomas. Here, BRAF is linked to thyroid tumor.